New hope for hard-to-treat lung cancer: combo therapy enters human testing
Disease control
Recruiting now
This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in about 76 people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the safest dose and see if the combination can …
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:54 UTC